The FDA has granted Relievant Medsystems investigational device exemption to conduct a larger clinical study of its Intracept basivertebral nerve ablation device. The 200-participant trial will be expanded to include 20 U.S. clinical sites, where the device will be tested for treating recurrent low back pain.
Relievant gets FDA OK for expanded back-pain-device trial
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||